Original ArticlePharmacognosy CommunicationsVol. 9 | Issue 4 | 2019 | pp. 135–138Open access
Corilagin: First Time Isolation from the Whole Plant of Phyllanthus maderaspatensis L.
- 1,
- 1,
- 1,
- 1,
- 1,
- 1*
- 1 R&D Centre, The Himalaya Drug Company, Bengaluru, Karnataka, INDIA.
Published in Pharmacognosy Communications
Correspondence: Ganesh Muguli
R&D Centre, The Himalaya Drug Company, Bengaluru, Karnataka, INDIA.
Email: dr.ganesh@himalayawellness.com
Copyright: © 2019 Manuscript Technomedia. This is an open access article.
- Published:
- Sep 25, 2019
- DOI:
- 10.5530/pc.2019.4.28
How to cite
Kochumadhavan, A., Mangal, P., Kumar, L. S., Meenakshi, B. M., Venkanna, B. U., & Muguli, G. (2019). Corilagin: First Time Isolation from the Whole Plant of Phyllanthus maderaspatensis L. Pharmacognosy Communications, 9(4), 135–138. https://doi.org/10.5530/pc.2019.4.28
Abstract
Introduction: Corilagin, an ellagitannin (chemical name β-1-O-galloyl-3,6- (R)-hexahydroxydiphenoyl-d-glucose), was previously reported from other species of Phyllanthus except Phyllanthus maderaspatensis L. Therefore, the aim of the study was to isolate corilagin from P. maderaspatensis and report it as chemo-marker. Methods: The whole plant of P. maderaspatensis was subjected to hot extraction and partitioning, followed by repeated column chromatography (silica, Diaion HP-20 and Prep HPLC). The observed LC‑MS/MS and NMR data were compared with reported literature to verify the structure of the isolated molecule as corilagin. Results: The LC-MS/MS chromatogram showed a peak at retention time 22.05 min, with m/z 633 for [M - H]− along with characteristic major fragments at m/z 463 [M - 170 - H]− and m/z 301 [M - 332 - H]−. The NMR results were also in accordance with literature. Conclusion: This is the first report on isolation of corilagin from P. maderaspatensis whole plant for standardization and quality control of the plant.
Keywords
Subject
Article metadata
| Title | Corilagin: First Time Isolation from the Whole Plant of Phyllanthus maderaspatensis L. |
|---|---|
| Authors | Abhilash Kochumadhavan; Priyanka Mangal; LM Sharath Kumar; Badugu Madhura Meenakshi; Babu Uddagiri Venkanna; Ganesh Muguli |
| Affiliations | R&D Centre, The Himalaya Drug Company, Bengaluru, Karnataka, INDIA. |
| Corresponding author | dr.ganesh@himalayawellness.com |
| Journal | Pharmacognosy Communications |
| Volume / Issue | Vol. 9, Issue 4 (2019) |
Also in this issue
- Editorialpp. 123–123
- Preliminary Evaluations of the Antibacterial Activity of Tasmannia lanceolata against Bacillus anthracis: Natural Resource Probing to Prevent Anthraxpp. 124–129
- Cordyline rubra Otto and A. Dietr. Leaf and Fruit Extracts Lack Antibacterial Activity and are Non-toxic in vitropp. 130–134
- Hematopoietic Effect of Amaranthus cruentus Extract on Cyclophosphamide Induced Toxicity in Ratspp. 139–142
- The Growth Inhibitory Activity of Tasmannia lanceolata (Poir.) A.C. Sm against the Food-poisoning Pathogen Yersinia enterocoliticapp. 143–148
Readers Also Viewed
Development and Validation of UV/visible Spectrophotometric Method for Estimation of Piroxicam from Bulk and Formulation
Sandip Mohan Honmane, Kunal Rajaram Yadav, Yuvraj Dilip Dange
Apr 23, 2025
Effects of Artificial Intelligence on Academic Performance of Library and Information Science University Students: A Meta-Analysis (2023-2025)
Kayode Sunday John Dada
Aug 6, 2026
Bridging Innovation and Impact: A Multidisciplinary Approach to Contemporary Research Challenges
Mueen Ahmed KK
Aug 11, 2026